LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Blood and Saliva Samples Can Be Used to Detect Genetic Markers for Liver Cancer

By LabMedica International staff writers
Posted on 29 Nov 2021
Print article
Illustration
Illustration

Doctors examining the markers of liver cancer have found that the disease can be recognized by RNA fragments in saliva and blood.

This discovery by doctors at the RUDN University (Moscow, Russia) is significant because of the need to develop ways to find liver cancer in people at risk before it is too late. Liver cancer is less common than other cancers, but it has lower survival rates. Sometimes it appears suddenly, but in most cases, it is preceded by other liver diseases. For example, liver cirrhosis due to hepatitis C. However, in this case, the development of liver cancer can occur imperceptibly. It is difficult to diagnose it in the early stages.

RUDN University doctors have found that microRNA (small sequences of RNA that do not encode genes but are involved in the regulation of their expression) can be a marker of liver cancer. Doctors took blood and saliva samples from 29 patients with cirrhosis, 24 patients with liver cancer and 21 healthy volunteers and compared the expression level of 10 different microRNAs in the samples.

Seven microRNAs that were found in the blood plasma outside the exosomes (the vesicles secreted by cells) were associated with liver cancer. Three of them were also found in saliva. This can be important for diagnosis, since saliva analysis is significantly simpler as the collection of the sample does not need a professional, the patients can do it themselves. The microRNAs found inside the exosomes may become even more effective marker of liver cancer. For them, saliva is even preferable for analysis than blood. Therefore, depending on what biological material is available, it is possible to estimate the development of liver cancer by exosomal and non-exosomal microRNAs.

"The incidence rate, along with other factors, including the reluctance of at-risk patients to systematically come to the research center for blood sampling, complicates the collection of samples to identify markers for early diagnosis,” said Alisa Petkevich, a researcher at the RUDN University. “A possible solution could be the use of biomaterial that does not require medical personnel for its collection, such as saliva. We proved that saliva is a promising source of exosomal and non-exosomal microRNAs. Exosomal microRNAs have shown a strong association with primary liver cancer in saliva samples.”

Related Links:
RUDN University 

Gold Member
Rotavirus Test
Rotavirus Test - 30003 – 30073
Verification Panels for Assay Development & QC
Seroconversion Panels
New
HIV-1 Test
HIV-1 Real Time RT-PCR Kit
New
Binocular Laboratory LED Illuminated Microscope
HumaScope Classic LED

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The UV absorbance spectrometer being used to measure the absorbance spectra of cell culture samples (Photo courtesy of SMART CAMP)

Novel UV and Machine Learning-Aided Method Detects Microbial Contamination in Cell Cultures

Cell therapy holds great potential in treating diseases such as cancers, inflammatory conditions, and chronic degenerative disorders by manipulating or replacing cells to restore function or combat disease.... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.